Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
Intracarotid urokinase with thromboembolic occlusion of the middle cerebral artery.
复制标题
颈动脉内尿激酶伴大脑中动脉血栓栓塞。
作者：
E. Mori;M. Tabuchi;Takashi Yoshida;A. Yamadori
对22例因急性血栓栓塞性大脑中动脉闭塞而发展为脑梗死的患者行颈动脉内尿激酶输注治疗。从出现症状到开始输注的平均时间和尿激酶的平均剂量分别为4.5小时和927,000单位。10例患者（45%）在尿激酶治疗后立即再通。再通成功的患者，在血流恢复后症状迅速改善。溶栓再通与神经功能缺损和计算机断层扫描显示的梗死体积的减少有关。梗死体积的缩小和功能结局与血流程度高度相关。4例发生梗死出血转化，3例发生可控制的颅外出血。这些结果支持尿激酶治疗急性血栓栓塞性大脑中动脉闭塞的安全性和有效性。
Intracarotid urokinase infusion therapy was performed on 22 patients with evolving cerebral infarction due to acute thromboembolic occlusion of the middle cerebral artery. Mean time from onset of symptoms to start of infusion and mean dosage of urokinase were 4.5 hours and 927,000 units, respectively. Immediate recanalization was achieved in 10 patients (45%) after urokinase therapy. In patients with successful recanalization, rapid amelioration of symptoms followed the restoration of blood flow. Thrombolytic recanalization was associated with reduction of neurologic deficits and of computed tomography-demonstrable infarction volume. The reduction of infarction volume and functional outcome correlated highly with the degree of reflow. Hemorrhagic transformation of infarction occurred in four patients and controllable extracranial bleeding in three patients. These results support the safety and efficacy of urokinase therapy for acute thromboembolic occlusion of the middle cerebral artery.
颈动脉内尿激酶对狒狒模型急性中风的有益作用。
影响因子：
8.3
作者：
DelZoppo,GJ;Copeland,BR;Waltz,TA;Zyroff,J;Plow,EF;Harker,LA
通讯作者：
Harker,LA